Erasca is now a fully funded fast follower in RAS-targeted oncology, with ~$1B pro forma liquidity and three potential ...

The onboard amenities are a significant part of the business class experience.

In the 8-week study, ATR-258 was well-tolerated and associated with an approximately 13% mean improvement in lower extremity muscle power in ...

Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

A new review details how the Runx1 and Gata2 transcription factors architect the epigenetic landscape of blood formation and ...

Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) patients ---- Low annualiz ...

A new review describes how NMDA glutamate receptors on myeloid cells drive calcium-dependent reprogramming toward ...

Zenas BioPharma (ZBIO) advances obexelimab for IgG4-RD with a May 2027 PDUFA, strong cash runway and key catalysts ahead—read ...

Corteva, Inc. (NYSE: CTVA) today announced it has successfully spun off its advanced seed and genetics business and will move forward as a leading, pure-play global crop protection company.

Agentic AI threatens to disrupt India e-commerce and advertising models as software replaces human browsing, shifting control ...

Being named the No. 2 private K–12 school in Texas is a real point of pride for our entire community.”— Dr. Ryan Kelly, ...